A Multicenter, Randomized, Double-Blind, Phase 2b Trial to Determine The Efficacy, Tolerability And Safety Of 3 Dose Regimens Of RDEA806 and Open-Label Efavirenz as Active Control in HIV 1-Infected, Antiretroviral Naive Subjects

Trial Profile

A Multicenter, Randomized, Double-Blind, Phase 2b Trial to Determine The Efficacy, Tolerability And Safety Of 3 Dose Regimens Of RDEA806 and Open-Label Efavirenz as Active Control in HIV 1-Infected, Antiretroviral Naive Subjects

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs RDEA 806 (Primary) ; Efavirenz
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Ardea Biosciences
  • Most Recent Events

    • 26 Mar 2014 According to the European Clinical Trials Database record, status changed from not yet recruiting to discontinued.
    • 14 Nov 2008 Status changed from planning to not yet recruiting, according to an Ardea Biosciences release.
    • 25 Jun 2008 The study is expected to be initiated in the third quarter of 2008, according to an Ardea Biosciences media release (9090499).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top